TRCT
TRDA icon

Tower Research Capital (TRC)’s Entrada Therapeutics TRDA Stock Holding History

Tower Research Capital (TRC)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Sell
1,670
-267
-14% -$3.06K ﹤0.01% 3448
2025
Q4 		$19.9K Sell
1,937
-5,421
-74% -$45.7K ﹤0.01% 3103
2025
Q3 		$42.7K Buy
7,358
+3,463
+89% +$20.3K ﹤0.01% 2655
2025
Q2 		$26.2K Buy
3,895
+2,703
+227% +$21.7K ﹤0.01% 3517
2025
Q1 		$10.8K Sell
1,192
-354
-23% -$4.41K ﹤0.01% 3608
2024
Q4 		$26.7K Sell
1,546
-4,818
-76% -$87.3K ﹤0.01% 2971
2024
Q3 		$102K Buy
6,364
+3,484
+121% +$54.9K ﹤0.01% 2224
2024
Q2 		$41K Buy
2,880
+2,445
+562% +$34.8K ﹤0.01% 3244
2024
Q1 		$6.16K Sell
435
-5,345
-92% -$75.6K ﹤0.01% 4421
2023
Q4 		$87.2K Buy
5,780
+4,777
+476% +$70.8K ﹤0.01% 2747
2023
Q3 		$15.8K Buy
1,003
+409
+69% +$6.44K ﹤0.01% 3590
2023
Q2 		$8.99K Sell
594
-698
-54% -$9.62K ﹤0.01% 4350
2023
Q1 		$19K Buy
1,292
+845
+189% +$11.3K ﹤0.01% 3514
2022
Q4 		$6K Sell
447
-2,061
-82% -$36.1K ﹤0.01% 4774
2022
Q3 		$40K Buy
+2,508
New +$31.8K ﹤0.01% 3360
2022
Q2 		– Sell
-2,485
Closed -$23K – 6523
2022
Q1 		$23K Buy
2,485
+7
+0.3% +$75 ﹤0.01% 3406
2021
Q4 		$42K Buy
+2,478
New +$60.1K ﹤0.01% 2909

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s TRDA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Entrada Therapeutics (TRDA) stake by 14% in Q1 2026, selling an estimated $3.06K and leaving 1,670 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3448.

Tower Research Capital (TRC) first reported a position in TRDA in Q4 2021 and has held it in 17 quarters since. The position peaked at $102K in Q3 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Tower Research Capital (TRC) held 1,670 shares of Entrada Therapeutics worth $21.1K as of Q1 2026.
  • Tower Research Capital (TRC) sold 267 Entrada Therapeutics shares in Q1 2026, an estimated $3.06K.
  • Entrada Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3448 holding.
  • Tower Research Capital (TRC) first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Entrada Therapeutics position peaked at $102K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.